Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Egyptian Journal of Medical Human Genetics [The]. 2014; 15 (1): 15-23
in English | IMEMR | ID: emr-154343

ABSTRACT

The genus Cocculus belongs to the family Menispermaceae which comprises about 35 species of shrubs or woody climbers. Only one species, Cocculus pendulus is found in Egypt. This plant is reported to have good medicinal values in traditional system of medicine. Despite the wide occurrence of C. pendulus in the Egyptian deserts, attention was paid only to its distribution and morphological description ignoring the biochemical constitution, the genome makeup and environmental aspects which are not given due consideration. Since no information about the genome of C. pendulus is available, the current study deals with molecular investigation of C. pendulus expressed by DNA fingerprinting of the young leaves of this plant using amplified fragment length polymorphism [AFLP] technique with four primer combinations. The obtained results revealed a total of 228 bands with an average of 57 bands for each primer combination, of which 61 bands were polymorphic [26.8%] ranging in size from 59 to 570 bp. The number of amplicons/primer pairs ranged from 48 [E-AGG/M-CAC] to 72 [E-AAC/M-CAG] while the number of polymorphic amplicons varied from 13 to 21 with polymorphism percentage of 22.03-29.17%. Thus the average number of polymorphic fragments/combinations was 15. In this regard, the combination E-AGG/M-CAC was more efficient as confirmed by computing the discriminating power [D] of all primer combinations. Also, the AFLP marker gives a complete informative and highly discriminative picture about C. pendulus as shown by [PIC = 0.99]


Subject(s)
Plants, Medicinal , DNA Fingerprinting/methods , Polymorphism, Genetic
2.
Journal of the Egyptian National Cancer Institute. 1984; 1 (3): 57-62
in English | IMEMR | ID: emr-106131

ABSTRACT

Seventy-four patients with Hodgkin's disease, lymphomas, and breast cancer were treated with vindesine 3 mg - 3.5mg/ m/[2]/week iv. Complete, partial and mixed responses were encountered in 16 of 26 patients with Hodgkins disease, in 9 of 24 lymphoma patients, and partial response in 4 of 24 breast cancer patients. Mild to moderate degree of peripheral neuropathy was encountered in 46 patients. Mild leucopenia was seen in 12 patients. It is concluded that vindesine is efficacious in Hodgkin's disease and lymphomas, and is recommended for combination chemotherapy regimes


Subject(s)
Humans , Male , Female , Breast Neoplasms/drug therapy , Vindesine/administration & dosage , Vindesine/adverse effects , Chemotherapy, Adjuvant
SELECTION OF CITATIONS
SEARCH DETAIL